Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 5 | 2017 | 58 | 1.000 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 23 | 0.440 |
Why?
|
| Aptitude Tests | 1 | 2013 | 3 | 0.430 |
Why?
|
| General Surgery | 2 | 2013 | 55 | 0.430 |
Why?
|
| Genetic Therapy | 2 | 2013 | 86 | 0.420 |
Why?
|
| Ileal Neoplasms | 1 | 2011 | 3 | 0.370 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 79 | 0.370 |
Why?
|
| Clinical Competence | 1 | 2013 | 210 | 0.360 |
Why?
|
| Herpesvirus 1, Human | 1 | 2010 | 2 | 0.340 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 19 | 0.340 |
Why?
|
| Genetic Vectors | 1 | 2010 | 59 | 0.330 |
Why?
|
| Laparoscopy | 1 | 2011 | 188 | 0.320 |
Why?
|
| Rosaniline Dyes | 1 | 2008 | 2 | 0.310 |
Why?
|
| Radioisotopes | 1 | 2008 | 13 | 0.310 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 368 | 0.300 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 93 | 0.300 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 411 | 0.220 |
Why?
|
| Immunotherapy | 2 | 2013 | 59 | 0.210 |
Why?
|
| Cancer Vaccines | 2 | 2012 | 7 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2012 | 47 | 0.180 |
Why?
|
| Sentinel Lymph Node | 1 | 2017 | 1 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2017 | 12 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 27 | 0.140 |
Why?
|
| Humans | 13 | 2017 | 27158 | 0.140 |
Why?
|
| Clinical Clerkship | 2 | 2013 | 30 | 0.130 |
Why?
|
| Opioid-Related Disorders | 1 | 2017 | 61 | 0.130 |
Why?
|
| Pain Management | 1 | 2017 | 143 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2017 | 142 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2017 | 425 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2017 | 73 | 0.120 |
Why?
|
| Animals | 6 | 2013 | 3625 | 0.120 |
Why?
|
| Gastroscopy | 1 | 2015 | 9 | 0.120 |
Why?
|
| Gastrostomy | 1 | 2015 | 9 | 0.120 |
Why?
|
| Adult | 5 | 2017 | 7918 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2017 | 230 | 0.120 |
Why?
|
| Patient Safety | 1 | 2015 | 38 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3546 | 0.110 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 75 | 0.110 |
Why?
|
| Animals, Laboratory | 1 | 2013 | 3 | 0.110 |
Why?
|
| Middle Aged | 5 | 2017 | 9031 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 146 | 0.100 |
Why?
|
| Hypopigmentation | 1 | 2013 | 2 | 0.100 |
Why?
|
| Vitiligo | 1 | 2013 | 3 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2013 | 7 | 0.100 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2013 | 7 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2013 | 14 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 33 | 0.100 |
Why?
|
| Education, Medical | 1 | 2013 | 46 | 0.100 |
Why?
|
| Students, Medical | 1 | 2013 | 58 | 0.100 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 2 | 0.100 |
Why?
|
| Laparoscopes | 1 | 2011 | 2 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 202 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 103 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 79 | 0.090 |
Why?
|
| Defective Viruses | 1 | 2010 | 1 | 0.090 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2010 | 2 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 374 | 0.090 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 31 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2010 | 58 | 0.080 |
Why?
|
| Virus Replication | 1 | 2010 | 50 | 0.080 |
Why?
|
| Mice | 2 | 2013 | 1414 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 140 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 106 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2013 | 1783 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2015 | 3525 | 0.080 |
Why?
|
| Patient Selection | 1 | 2010 | 197 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 111 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 6 | 0.080 |
Why?
|
| Coloring Agents | 1 | 2008 | 14 | 0.080 |
Why?
|
| Research Design | 1 | 2010 | 187 | 0.080 |
Why?
|
| Male | 6 | 2017 | 14821 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 138 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 256 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 246 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 667 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 316 | 0.070 |
Why?
|
| Aged | 4 | 2017 | 9084 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 485 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1802 | 0.060 |
Why?
|
| Female | 5 | 2017 | 15269 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2008 | 628 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2008 | 1901 | 0.050 |
Why?
|
| Vaccines, DNA | 2 | 2012 | 6 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 2026 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 216 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2017 | 928 | 0.040 |
Why?
|
| Pain Clinics | 1 | 2017 | 4 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 5 | 0.030 |
Why?
|
| Lymphedema | 1 | 2017 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 331 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 93 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 179 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 4831 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 261 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 133 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 111 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 350 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2017 | 226 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 804 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 8 | 0.030 |
Why?
|
| Antigens | 1 | 2013 | 11 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2013 | 44 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 105 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2013 | 35 | 0.030 |
Why?
|
| Vaccination | 1 | 2013 | 35 | 0.030 |
Why?
|
| Forecasting | 1 | 2013 | 92 | 0.030 |
Why?
|
| Transfection | 1 | 2013 | 121 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 107 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2013 | 123 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 84 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 99 | 0.020 |
Why?
|
| Disease Management | 1 | 2013 | 104 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 162 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 101 | 0.020 |
Why?
|
| Anxiety | 1 | 2013 | 156 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 126 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2012 | 7 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 30 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 312 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 433 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2013 | 234 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 274 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 672 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 109 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1154 | 0.020 |
Why?
|
| United States | 1 | 2013 | 2066 | 0.020 |
Why?
|